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ABSTRACT

,

, .

Previous studies have shown that when R-flurbiprofen

(R-FB) is administered in the Min/+ mouse model it can

cause the prevention and regression of intestinal tumors.
To determine the rate and mode of action at which

preexisting tumors regress, 72-day old Min/+ mice were
administered R-FB or vehicle control for 0, 4, 10, 21 and

42 days;.

After necropsy tumor loads and apoptotic indices

(AI) from normal and tumor appearing tissues were obtained.
The data obtained from. Min/4: mice administered R-FB

demonst|rated: 1) a steady decrease in the total number of
developed tumors over time; 2) some involvement of
increasing the AI in tumor regions, 3) a significant
increase of the AI in normal appearing crypts of the small
intestine, and 4) no change in the AI of normal appearing

villus regions.

Increased incidence of apoptosis in the

crypts of normal appearing tissue may explain the tumor

prevention activity of R-FB.

Although there was some

evidence of an increased incidence of apoptosis in tumor

regions there was not an overall decrease in tumor
diameters.

Because of this, the possible roles of

apoptosis and desquamation in tumor regression remain
undefined.
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CHAPTER: ONE

INTRODUCTION

Background
Colon Canqer

In the United States there is an .average lifetime risk

of over 6% for developing colon cancer which is considered
to be high-risk.

These statistics piace coipn cancer as.

the third most cominon cancer and. the second leading Cause
of death due to.cancer in the U.S.

Each .year an estimated

15.0,000 people are diagnosed with colon . Cancer and 55,:00O
people die of this disease.

In spite .of the enormous

efforts to improve treatment and develop cures for advanced

disease:., the overall mortality rates for most forms.,of
epithelial cancers,:. ihclading colon cancer, have not . , .

declined in the past. 25 years (Conley, Kaplan and Arbuck.
1998 and Hong land Spprn 1997).

In light of this

information much, of current research, is. toe
and Other risk factors to. uncover the

on: genetic,
;

predisposition Ifor colorectal;cancer in various
populations. ^ ^ ^ ^ ^ ^ ^ ^ .

1

Cancers, ■including:colorectal cancer, involve mutated

gehes that, when expressed, produce molecules that

influen ;e normal cellular activities.

Alterations in these

activities can become devastating if they interfere

normal

regulation of cellular growth mechanisms.

with th

In

normal Situations, mutations in the genome occur on a
regular basis, but are dealt with by mechanisms such as:
DNA rep air, cell cycle arrest, and/or apoptosis..

Although

DNA rep air and cell cycle arrest play an important part in

salvaging a genetically mutated cell, it is apoptosis which
acts

the ultimate backup plan by preventing damaged and

as

unwante d

cells from replicating.

cell de ath"

form of

Apoptosis or "programmed

is a morphologically and biochemically distinct

cell death that can be triggered by a variety of

extracellular

agents.

Apoptosis occurs during normal

development as well as in various adult pathophysiological
states.

a

Apoptosis plays an important role in organisms as

counterbalance

Fisher

1997).

to cellular proliferation (McGill and

Cellular proliferation is important to form

and maintain tissue, but can become harmful if it is not
balance;d,or held in check by apoptosis.
between

The balance

these two processes is vital and the consequences

of an imbalance can result in the development of cancer
(Foster 2000).

Colorectal cancer arises in a multistep fashion.that

can take 10-15 years in humans.

Accumulating mutations in

several: genes can result in abnormalities of cellular
growth regulation.

These genetic alterations transform the

normal epithelium into hyperplastic regions, leading to
adenomai formation and eventually carcinoma (Winawer 1999

and Marian 1996).

During this multistep process in

colorectal cancer, cells may develop mutations in the

following key genes: the adenomatOus polyposis coli {APC),
p53 tumor suppressor genes, the Ras oncogene, and various

genes that mediate DNA mismatch repair (Shiff and Rigas
1999). : The ARC gene has beeji considered the "gatekeeper"

of colonic epithelial cell proliferation, and inactlvation
of this.gene is required for net cellular proliferation,
i.e., imbalance with apoptosi.s (Umetani et al. 2000);.

In

the intestine, APC protein levels increase at the c.rypt-

villus boundary where cell migration from the crypt is

crucial and where cells accumulate during adenoma formation
(Nathke■et al, 1996) .

The APC gene is found to be mutated

in over. 80% of. sporadic colorectal adenomas and. carcinomas.
{.Tolinspm, Ilyas and Novelli. 1997.) .

The . Pas gene codes . for

a GT.P-binding protein that functions as a ..signal. transducer

of extracellular stimuli to. regulate cellular proliferation

and differentiation

the Ras

(Finco et al. 1997).

The function of

protein is to activate transcription factors

(i.e. N -kB) and pathways that, in return, influence the
express>ion

of other genes resulting in overall cellular

survival.

Oncogenic mutations in Ras, considered to be

required for cellular transformation, occur in 50% of

colorectal tumors, predominately in larger adenomas and
carcinomas (Finco et al. 1997 and Marian 1996).

Another

gene, p53, also plays a role in cancer development.

The

normal function of p53 involves sequence-specific DNA

binding that promotes cell-cycle arrest or apoptosis in
response to a variety of cellular stresses (Lowe 1999).
Evidence suggests that mutations in p53 lead to a reduction
of apoptosis and rapid tumor progression (Smith et al.
1995). In. addition, the gene for p53 is found mutated in

75% of late stage adenomas of colorectal cancer (Toiinsom,

Ilyas and Novelli 1997 and Marian 1996).

Although there

are many other genes that are related to colorectal cancer,
they are less common then APC, Ras and p53 and their roles

in the piathophysiology of colorectal cancer are still under
investigation.

Molecular Targets

Characterizing cancers for genetic mutations involved

in carcinogenesis and the altered activities they influence

have helped researchers discover and/or focus on
chemotherapeutic agents that are specific for those
molecular targets.

In theory, interfering with the

activities of genes that are responsible for the loss of
cellular regulation should restore the ability of affected
cells to undergo apoptosis (Wang et al. 1999).

For

example, the gene for inducible cyclooxygenase, a key

enzyme for the formation of prostaglandins from arachidonic
acid, is overexpressed in most gastrointestinal tumors.
There are two known isoforms of the cyclooxygenase

enzyme, cyclooxygenase-1 and -2 (COX-1 and COX-2,

respectively).

The COX-1 enzyme is constitutively

expressed and is considered to be responsible for the

prostaglandin synthesis required for physiological or
"housekeeping" functions of the cell.

The COX-2 enzyme,

although constitutively expressed in selected tissues, is

inducible by a variety of extracellular and intracellular
stimuli and is involved in inflammation, mitogenesis and

specialized signal transduction (Kam and See 2000).
gastrointestinal tract, cyclooxygehase-synthesized

In the

prostaglandins, in particular prostacyclin and PGE2,
normally act as cytoprotective agents that regulate gastric
acid and mucus production and vasodilation of the gastric

'

' i

' •

mucosa (Kam and See 2000).

However, when, the COX-2 gene is

overexpressed, there by causing prolonged high levels of

prostaglandins, tumor growth may be promoted.

In human

colorectal carcinomas there is a positive relationship

between COX-2 expression and the size, invasiveness and
stage of the carcinoma (Fujita et al. 1998 and Sheehan et
al. 1999).

Although the mechanism for increased COX-2

expression is not completely understood, it is known that
oncogenic Ras activates NF-kB, a transcription factor found

to be responsible for the increased expression of COX-2.
Increased COX-2 then leads to increased prostaglandin

synthesis and ultimately inhibition of apoptosis (Mayo et
al. 1997 and Kojima et al. 2000).

Consequently these steps

are considered as early and central events in colon
carcinogenesis.

Because of the role that COX-2 and NF-kB

may have in the progression of colorectal adenomas and
carcinomas, they have become important molecular targets

for drug development for the prevention and treatment of

colorectal cancer (Prescott and White 1996 and Hong and
Sporn 1997).
Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs),

including aspirin have been used for many years for the
treatment of inflammatory diseases such as arthritis. .

'

Numerous reports from human epidemiological studies, animal
models, and in vitro experiments have all suggested that
the administration of NSAIDs represents a potential option

in the chemotherapy and chemoprevention of colorectal

cancer (Gupta and DuBois 1998).

Most NSAIDs are considered

cox-inhibitors given that they inhibit both COX-1 and COX-2
to the same degree.

However, because these NSAIDs are

unable to distinguish between the two COX enzymes,
inhibition of COX-1 leads to the blocking of the

cytoprotective actions of prostaglandin thus they are
implicated in gastrointestinal (GI) toxicities involving
gastric mucosal erosions (Wallace et al. 1998).

Because

traditional NSAIDs exhibit GI toxicities, a new generation

of NSAIDs "COX-2 inhibitors" was evaluated for the ability

to selectively inhibit the COX-2 enzyme (Fosslien 2000).
Although predominately from in vitro and animal studies,
evidence indicates that these COX-2 inhibitors have

maintained their anti-neoplastic potential (Kawamori et al,
1998 and Stolina et al. 2000).

However, COX-2 inhibitors

such as Celecoxib and Vioxx seem to be safer than

traditional NSAIDs, though clinical trials have
demonstrated that they are not completely free from GI
toxicities.

Because of the continued GI toxicities, the

FDA still requires the manufacturers of the COX-2
inhibitors to carry package warnings similar to the
traditional NSAIDs (Feldman and McMahon 2000).
Alternate Mechanism

Although there is mounting evidence that COX-2
inhibition plays an important role, in the anti-neoplastic
effects of NSAIDs, there is also evidence of a second
mechanism of action.

Studies indicated that COX-2

inhibitors maintain their anti-proliferative activities
even in colon cancer cell lines that lack COX-1 and COX-2

expression and therefore lack the ability to produce

prostaglandins (Smith, Hawcroft and Hull 2000 and Hanif et
al. 1996).

While the alternate mechanism is currently

unknown it is possible that inactivation of NF-kB could be a
candidate.

NF-kB is a ubiquitous, rapid response transcription

factor that regulates several classes of genes including
those for cytokines, growth factors, other transcription
factors and, as previously mentioned, COX-2 (Lee and
Burckarc 1998 and Kojima et al. 2000).

A common theme for

all of these NF-kB regulated genes is their involvement with
cellular survival.

It appears that NF-kB plays a central

role in inhibiting apoptosis allowing normal cells to

progress towards transformation (Martin, Schmid and
Hofer-Warbinek 1999).

It has been shown that some of the

traditional and COX-2 inhibiting NSAIDs inhibit NF-kB either

directly or indirectly (Yamamoto et al. 1999).

The ability

of NSAIDs to inhibit a transcription factor, such as NF-kB,

which has such broad regulatory activities, may be one of
the reasons NSAIDs also have many potential uses.
Cyclooxygenase Inhibition

Several classes of NSAIDs are chiral compounds and
exist as two enantiomeric forms (R- and S-).

Representatives of chiral compounds from the propionic acid
class of NSAIDs are ketoprofen, ketorolac, and

flurbiprofen.

Traditionally, the activity of NSAIDs was

assessed based on their ability to inhibit the COX enzymes.

These NSAIDs, in racemic (rac; mixture of both R- and

S-enantiomers) form, are potent COX inhibitors and are
extensively used as therapeutic agents for
anti-inflammatory and analgesic purposes (Carabaza et al.
1996 and Muller et al. 1990).

However, when each

enantiomer is tested separately it is found that the

S-enantiomer is predominately responsible for the COX

inhibiting capabilities (Carabaza et al. 1996).

Such is

the, case for Flurbiprofen (FB), the, R-enantiomer (R-FB) is

considered a non-COX inhibitor due to its high IC50
(concentration at which 50% of the enzyme activity is

,,

inhibited) for the COX-1 and COX-2 enzymes (400 nM and

1400 nM, respectively).

While the S- enantiomer of

Flurbiprofen (S-FB) is vastly more potent than R-FB with an
IC50 for'COX-l and COX-2 of 2.7 nM and.2.5 nM, respectively
(Carabaza et al. 1996),.

S-FB is 148 and 560, times more

potent at inhibiting COX-1 and COX-2, respectively, than
R-FB, and it was for this reason that R-FB was considered
relatively inactive and was;labeled as a non-COX inhibiting
enantiomer.

Although considered a non-COX inhibitor, R-FB has

demonstrated chemoprotective activities in various animal
models.

In a 30-day study with R- and S-FB (McCracken et

10

al. 1996), large bowel epithelial cell proliferation rates
in laboratory rats were measured by labeling the crypts Of
Lieberkiihn with bromodeoxy uridine (Brd-U) immunostaihing.

In this study both R- and S-FB at 6.3 mg• kg"^• day"^
significantly reduced the percent of S-phase cells, when

compared to the control animals given vehicle alone
(1% CMC, carboxymethylcellulose).

This study also

demonstrated that S-FB is linked to ulcer formation, which

is believed to be due to its COX inhibiting properties.

There was an ulcer area approximately 20 times larger with

S-FB than with R-FB.

Although the ulcer area of R-FB was

greater than that found with vehicle control (which
exhibited no ulcers), the amount of ulceration was minimal.
This minimal ulceration may have been the result Of S-FB

formation via a process called epimerization or
bioinversion, which is an enzymatic conversion of one
enantiomer into the other (Wechter 1994).

Because rats

bioinvert R- to S-FB at a rate of 6 to 10%, there may have

been enough S-FB present in these experiments to cause
ulceration. However, in human clinical trials with R-FB,
the rates of bioinversion to S-FB have beenrfound to be
minimal

(< 0.5 % bioinversion) at doses greater than

11

1200 mg day ^ and these have been associated with minimal GI
toxicit: es

(Quiggle et al. 2000).

R-Flurbiprofen

The minimal side effects of R-FB clearly give it an

advantage over other NSAIDs.

To evaluate the effectiveness

of R-FB in preventing intestinal adenoma formation, a

multiple intestinal neoplasia (Min/+) mouse model was used.
The Min/+ mouse is heterozygous for a nonsense mutation in
the APC gene and serves as a murine model for the human
disease familial adenomatous polyposis (FAR) (Moser, Pitot

and Dove, 1990; Su, et al. 1992).

Weanling Min/+ mice

(30 days old) given doses between 2.5 and

25 mg R-FB• kg~^•day~^ for 6 weeks, exhibited a dose-dependent
inhibition (40% to 90%) of adenoma formation (Wechter et

al. 199"^).

In these studies, mice bioinverted R- to S-FB

at 6.9% and 16.6% in the 2.5 and 25 mg R-FB* kg"^* day~^ dose

groups, respectively.

At lower doses (<20 mg*kg~^*day~^) the

amount of S-FB was minimal and resulted in little

ulceration or other side effects.

However, at higher doses

(>20 mg* kg"^*day~^) bioinversion was significant (16.6%) and
resulted in increased ulceration.

These toxicities

resulted in 35% of the animals dying from causes associated

12

with S-FB toxicity.

Because mice exhibit higher R- to S-FB

bioinversion rates, S-FB concentrations equivalent to those
due to R- to S- bioinversion were tested in the Min/+ mice

to determine if the activity of S-FB causes tumor
inhibition.

This study found that the R-FB inhibition of

tumor formation could not be attributed entirely to the
R- to S-FB bioinversion (W.echter et al. 1997).
A study that supports the potential use of R-FB as a

chemotherapeutic agent for preexisting tumors was performed
using the Min/+ mice.

In this study the mice were allowed

to develop tumors, leaving, them untreated until 72 days of

age [tumor loads are approximately 25 tumors/mouse in

control groups; historical data (Wechter et al. 1997)].

At

that point, the mice were treated with 10 mg*kg~^*day~^ R-FB,
which had previously proven to be the optimal dose.

These

mice were treated for six weeks and then intestinal tumors
were quantified.

of tumors

There was .a significant inhibition (85%)

in the treated group, when compared to the

control

group (.1% CMC).' The average tumor load of treated

animals

were approximately 4 tumors/mouse while the control

group had

approximately 29 tumors/mouse.

This study

indicates that R-FB can possibly be used not only as a.

:■ ■ 13-

chemopreventive agent but also as a chemotherapy to
eliminate and reduce existing colon tumors.

I

, .

;

.

JnI vitro studies involving cancer cell lines and
various NSAIDs (i.e. aspirin, naproxen, indomethacin and

piroxicam) have displayed an IC50 for proliferation ranging
between 100 to 600 pM (Shiff et al. 1996).

These NSAIDs

(with the. exception of aspirin) also initiate apoptosis in
the tested colon cancer cells (Shiff et al. 1996).

To

determine if R-FB was also active in vitro, experiments

were performed on the colorectal cell line LS174T.

In

performing proliferation analyses an IC50 for proliferation
was obtained at approximately 600 pM R-FB.

Electrophoretic

profileL of DNA from LS174T cells exposed to R-FB for
24 hours revealed DNA laddering, a characteristic of

apoptosis (Quiggle, unpublished data).
I

.

The ability of R-FB

,

to induce apoptosis in vitro, may indicate the method in

which it,acquires its chemopreventive and chemotherapeutic
activities in in vivo studies.

R-flurbiprofen has also been implicated in NF-kB
inhibition.

In vitro studies involving lipopolysaccharide

(LPS) induced NF-kB activation have demonstrated that R-FB

inhibits NF-kB activation (Tegeder 2000).

14

This study

demonstrated that R-FB.inhibits the LPS-induced nuclear

translocation of NF-kB, consequently blocking DNA binding.
biting NF-KB-dependent gene expression.

and inh

The ability

of R-flurbiprofen to inhibit NF-KB, may explain the
apoptosis-inducing and anti-inflammatory activities
associated with this drug.

Study Objectives

Although past"studies have demonstrated that R-FB was
effecti"*re

Min/+

mo

at inhibiting and eliminating colon tumors in the

use model, the rate and mode of eliminating

existing tumors remains unknown. (Wechter et al. 2000 and
Wechter

study

et al. 1997).

th e

pharmacodynamics of R-FB on tumor regression in

Min/+ m; ce.
evaluated

The purpose of this study was to

The following pharmacodynamic parameters were

in response to R-FB treatment: 1) the incidence

of apoptosis in the normal appearing crypt and villus

regions; 2) the incidence of apoptosis within tumors; and
3) the 2 ate at which the number of tumors decreased.
Understanding

number

R-FB pharmacodynamics in reducing tumor

dan further test its potential as a chemotherapeutic

agent and

to aid in the design of future studies by

optimiz ng for length of, treatment and timing.

15

Although

understanding

the .mode by. which tumors regress could help

support in vitro work conducted.with R-FB, it could also

help determine potential biomarkers for use in future
animal and human studies..

Biomarkers from relatively small

samples can be used as intermediate indicators of
effecti /eness in cancer prevention and treatment studies,
Biomarkers

are especially important in human

chemopreventive studies due to the constraints and

longevi:y of human studies.
Study Design

The design of the proposed study was to administer

R-FB to 72-day old Min/+ mice for up to 42 days.

In order

to capture the process of tumor reduction, animals were
necropsied at various time points.

At each time point

animals were evaluated for tumor loads and presence of

apoptotic cells along the small intestine..

Apoptotic cells

were assessed using a terminal deoxynucleotidyl
transferase-mediated dUTP-digoxigenin nick end labeling

(TUNEL) assay..

Apoptotic indexes from the middle, to distal

section of small intestines were determined in the crypts

and. viltLi of normal appearing tissue and of tumor regions.

16

study L. mitations

A foreseeable limitation Of this, experiment was the

ability to obtain sufficient number of.histologic samples
of tumor regions in animals treated with R-FB.

This was

due to the anticipated decrease in the tumor load of the
animal.

However, to increase the probability of obtaining

a histological sample containing a cross-sectioned tumor.
samples were cut at several places throughout the evaluated
region.

This was believed to give a sufficient number of

observations in order to be statistically evaluated.

17

CHAPTER TWO

MATERIALS AND METHODS

Materials
Animals

Fx

ty-four weanling female C57BL/5J-APC'^^'^/+ mice

26-32 da ys

of age were obtained from Jackson Labs

(Bar Ha rbor, ME).
Animal

They were housed in the Loma Linda

Care Facility with,a 12-hour-on:12-hour-off light

cycle.aifid controlled for humidity (50%) and temperature

(72°F)

The animals were given tap wafer and pelleted chow

(AIN-93G, Dyets, Bethlehem, PA) ad libitum.

.

Chemicals

R-Flurbiprofen (R-FB) (99% purity; >99% enantiomeric
excess) was provided by Wycoff Inc. (Lot# 18AZ26C).

All

Other chemicals were commercially available from Fisher
Scientific, with purity of reagent grade or better.
Drug Preparation

The R-FB was prepared as a suspension in
1% carb Dxymethylcellulose,

tissue

(CMC) by homogenization with a

idmogenizer, then heating to 60°C for approximately

15 minutes, followed by rehomogenization.

The amount of

drug pr ipared was based on a dose volume of 1.0 ml-0.3 kg

18

and the daily dose of 10 mg-kg"^-day"^ (final concentration

of the suspension was 3.0 mg R-FB*nil~^ in 1% CMC).
Carboxymethylcellulose (1% CMC) was used as the vehicle
control

Methods

Study Design

R-Flurbiprofen Administration.

Upon arrival, AVID

microchips (AVID Identification Systems, Inc., Norco, CA)
were inserted subcutaneously into the mice for

identification purposes.

The mice were then randomly

assigneql into R-FB and vehicle-treated groups (6 mice per
group) for each treatment time period (0, 4, 10, 21 and 42

days; with the exception of day-0, which only consisted of
a control group) by the Monte Carlo method (Niederreiter
1992).

Following randomization, the mice were fed only the

AIN-93G diet until 72 days of age.

Once aged, treatment

began and all mice were administered drug or vehicle on a

daily basis, by oral gavage.

All mice were weighed weekly

and the dosage was recalculated accordingly.
Necropsy.

After the completion of the designated

treatment periods, the animals were necropsied.

Necropsies

were performed 2 hours after the animals last administered

19

dose.

At necropsy, the mice were anesthetized by an

intraperitoneal (i.p.) injection of 50-mg-kg~^- ketamine and
10-mg• kg~^•xylazine solution.

Following the midline

abdominal incision, exsanguination via cardiac puncture was

performed with a heparinized syringe.

From the blood

obtained, the hematocrit was determined and a 500 pi

aliquot was set aside on ice for determination of plasma
drug levels (see below).

The animals were then

disemboweled between the stomach and rectum and the

intestinal tissue was processed as described below.

Analysis of Plasma Drug Levels.

Whole blood obtained

2 hours after the last administered treatment was used for

determining plasma drug levels.

Plasma was obtained by

centrifugation (13,000 x g for 5 minutes) of the whole
blood.

An aliquot of 100 pi was acidified with 20 pi of

2 M HCl and vortexed for 30 seconds.

To the acidified

solution, 2.0 ml of a ice-cold hexane:ether (4:1) solution
was added, followed by 3 minutes of vortexing.

The organic

and aqueous layers were separated by sonication (to reduce
emulsification) and centifugation (13,000 x g for

15 minutes).

A 1.5 ml aliquot of the organic layer was

removed and placed into a clean tube and allowed to air
dry.
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Once dry, the residue was dissolved in 150 yl of a

hexane:isopropanol:acetic acid (97:3:0.5) solution of which
100 pi v/as analyzed by high performance liquid

chromatography (HPLC) analysis.

The HPLC analysis was

conducted on a Beckman System Gold Chromatography System
(version 5.1) running on a PC-compatible computer.

The

dissolved plasma residue was applied to a S,S-Whelk-0
column (4.6 x 250 mm; Regis Inc., Morton Grove, XL), and
was eluted with a hexane:isopropanol:acetic acid (97:3:0.5)

solution at 1 ml per minute for 15 minutes.
monitored at 254 nm.

The eluent was

Standard curves were obtained by

adding rac-FB to 200 pi of mouse whole blood over a range

of 1-40 pg ml"^ of blood.

The plasma was analyzed as

described above.
De

:ermination of Tumor and Ulcer Load.

For

determination of total tumor load, the gastrointestinal
tract was isolated.

The three small bowel segments were

excised as the proximal 4 cm (duodenum), the middle 4 cm

(jejunum), and the distal 4 cm (ileum).

These sections

were cut longitudinally, washed with PBS (137 mM NaCl, 3 mM
KCl, 4 iriM Na2HP04, and 1.5 mM KH2PO4, pH 7.1) and mounted on

bibulous paper with the mucosal side up.

These segments

were fixed for approximately 24 hours in 10% neutral
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buffered formalin (Fisher cat# HC-200-1 GAL) then
transferred into a 70% ethanol (EtOH) solution until

analysis.

Tumors and ulcer.loads were determined independently

by two observers in blind analysis.

The segments were

soaked in 0.05% aqueous methylene blue (Sigma-Aldrich) for

approximately 10 minutes and then viewed with an Olympus
SZH darlc-field stereomicroscope at a, constant, magnification
(20X).

After tumor identification (Figure lA), the tumor

diametej: was obtained by measuring the tumor at its widest

point.

Measurements were taken using an eyepiece reticle

that was standardized to a stage micrometer.

The smallest

measurable tumors were approximately 0.2 mm in diameter.

Tumor areas were calculated as: area = [ti(diameter/2)^].
Average tumor area was obtained by taking the average of

all tumor areas for each animal then reporting the average

of each group.

The tumor number reported was- the average

of the total number of tumors counted from all the segments

(proximal, middle and distal) for each animal. Ulcers were
identified as non-raised areas, devoid of any villi

exposing underlying mucosa, and encircled by tightly bound

abnormal appearing villi.

The ulcer number reported was
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Figure 1. Small intestine tumors and villus stained for

apoptosis in C57BL/6J-APC"^"/+ mice aged to 72 days old then
administered R-flurbiprofen orally for Up to 42 days.

the average of the total number of ulcers counted for each
individual animal.

.

Tissue Preparation and Analysis

Tissue Histology.

The remaining segment of the

middle-distal small bowel was, washed with PBS to thoroughly
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clean the
into 3

mucosa of any debris.

This section was then cut

to 4 equal portions which were mounted in parallel .

position on porous tape and rolled up to maintain straight
intestinal segments.

The intestinal segments were then

10% neutral buffered formalin for approximately

fixed in

24 hours and then transferred into a 70% EtOH solution for

24 hours.

The segments were dehydrated by incubating in a

series of solutions (70% EtOH, 90% EtOH, 95% EtOH, 10!0%

EtOH, xylenes and then a 1:1 xylenes-paraffin solution) for

two 30-minute incubation periods in each solution.

After

the dehydration steps, the segments were embedded
longitudinally into paraffin and stored until sectioned.
Apoptotic Cell Detection.
was used

A microtpme (RMC MT-920)

to cut 4 am sections from the paraffin embedded

intestinal

samples.

Cut sections were floated in a warm

water bath

then placed onto aminoalkylsilane treated slides

(Polysciences, Inc, Los Angeles/ OA), to aid in tissue
attachme nt.

Slides were then placed in a 55° C oven for

5 minutes then allowed to cool to room temperature.
slides

The

were then dewaxed and rehydrated. by incubating../in a

series of solutions (xylenes, 100% EtOH, 95%■EtOH,
90% EtOH, 70% EtOH and PBS)

periods in each solution.

for two 5-minute incubation

The TUNEL assay was performed
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.

,

utilizing the TAGS

2 TdT^DAB In Situ Apoptosis Detection

Kit (Travgen Cat # , 4810-^30K).

exposed

The tissue samples were" then

for 30 min to 7,5-pl of Cytopore™, (saponin-based

permeab lization and blocking agent; Trevigen).
was washed

Each slide

twice for 2.minutes in deionized water.

Mucosal

endogenous peroxidase enzymes were inactivated by soaking
the slides

in a 3% hydrogen peroxide-methanol solution for

5 minuteis,

then washing them in PBS for 1 minute.

amples were immersed in a TdT labeling buffer

tissue

(IM TACS

Safe-TdT buffer, 0.5 mg ml^^ BSA, and 0.6 mM

2-mercaptoethanesulfonic
Excess b uffer

around

The

acid; Trevigen) for 5-minutes.

was removed from the slides by blottingi

the tissue samples.

reaction

A, 50 pi volume' of labeling

mix [5 pM Biotinylated dNTP mix, IX Mn^"^ cation

solution,

TdT enzyme (cat# 4810-30-05; Trevigen).] was added

and incubated

chamber.

for 60 minutes at 37°C in a humidified

The reaction was stopped by immersing the slides

in a TdT stop buffer (10 mM EDTA, pH 8.0 in deionized
water) for 5 minutes and washing each twice in PBS for
2 minutes.

Tissue samples were incubated at room

temperature for 10-minutes in 50 pi of a Streptavldin-HRP
(horseradish peroxidase) solution in PBS, then washed twice
in deionized water for 2 minutes each.
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Each slide was

immersed in DAB solution (Diaminobenzidine, 0.03% hydrogen
peroxide, in PBS) for 2 minutes then washed twice in
deionized water for 2-minutfes,

The slides were

Gounterstained with Methyl Green (1.0% Methyl. Green in
0.1 M sodium acetate, pH 4.0) for 10 minutes and then

dipped 10 times sequentially into deionized water,
95% EtOH:, 100% EtOH, and 100% xylenes.

The tissue samples

were then mounted under glass cover slips using Permount®
(Fisher Scientific, cat# SP15-500) mounting media.
Identification and Counting of Apoptotic Cells.

An

observer (blinded to treatment) counted normal and

apoptotic cells from 50 half-crypt (from bottom to top on
one side

of a crypt) and 50 villus regions (from top to

bottom on one side of the villus) for each mouse.

A

0.15 mm^ area (estimated to contain 3000 cells) was counted
for each tumor region (if present up to 10 tumor regions
were counted).

The apoptotic Index (AI) was defined as the

total number of apoptotic cells divided by the total number

of cells counted per region, multiplied by 100.
Morphological traits such as condensed nuclei and cellular
shrinkage were taken into consideration in conjunction with
the biochemical assay used to confirm apoptosis.

However,

in most cases, normal cells were identified by the presence
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of a dark blue nucleus and light colored cytoplasm, while

apoptotic cells were identified as having a dark brown
nucleus

and clear to light blue cytoplasm (Figure IB).

Necrotic cells were identified as having a dark brown
nucleus

and light to dark brown cytoplasm.

Statistical Analyses

Descriptive analyses were applied to find the mean and
standard

deviation for the represented data.

Descriptive

statistics were performed on all data using the KolmogorovSmirnov Test to test for normal population distribution and

Levene Statistic to test for homogeneity of variance (SPSS®
Base 9.0 Applications Guide. [1999]).

For normal

distributed data (all data with the exception of AI for

tumor regions, fused villi and ulcer), ANOVA was applied.
If the ANOVA test was found to be significant (p < 0.05),
the multiple

comparisons test of Games-Howell was applied

with a significance

Guide. [1999]).

of p < 0.05 (SPSS® Base 9.0 Applications

For nonparametric data (only AI for tumor

regions, fused villi and ulcer), the Kruskal-Wallis Test

was applied (SPSS® Base-9.0 Applications Guide. [1999])
this test

If

.was found to be significant (p < 0.05), the Mann-

Whitney test was applied with a 2-tailed significance of p <
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0.05.

For comparisons not significantly distinguishable by

either ANOVA or Kruskal-Wallis, no further analysis was
performed.

Analyses were performed using SPSS for Windows

(Release 9.0.0 [18 Dec 1998]).
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CHAPTER THREE

RESULTS

Safety and Tolerance
Dose

To

erability

Overall the mice tolerated the administration of R-FB

well.

However, as expected signs of anemia (pale-looking

muzzle and paws) were observed in the Day-42 vehicletreated group and this was supported by decreased
hematocrits (HOT) measurements taken at necropsy.
vehicle

The

treated groups showed stable HOT of approximately

35%, up to Day-21 of treatment (93 days of age) relative to

the Day-10 vehicle-treated group (Table 1). ,However, the
HOT for the Day-42 vehicle-treated group decreased by

approximately 25% when compared to the previous groups.
the other hand, the HCTs for the R-FB treated groups

increased throughout most of the study and by day 42 had

increased to approximately 40% from the Day-0 vehicletreated. group and approximately 75% from the Day-42

vehicle-treated group '(Table 1).
Drug Bioinversidn

To determine plasma drug levels in the mice, blood was
collected at the approximate Cmax (maximum plasma drug
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On

Table 1.

Tolerability of R-Flurbiprofen Administered

Orally l:or up to 42 Days in C57BL/6J-APC'*^^"/+ Mice Aged to
72 Days Old.

HCT
Treatment

(%)

% Change
R-FB'
B. Wt^
.

(|ig-ml

S-FB'
-1

({xg*ml

Bioinversion^
(%)

Day 0
None

33 ±8

0 + 0

ND

ND

Day 4
VC

35 + 6

2 ± 1

ND

ND

R-FB

34 + 5

0 ± 1

50 ±19

3 + 0.2

VC

35 + 4

1 ± 2

ND

ND

R-FB

38 ± 5

2 ± 2

68.+ 11

7 ±2

VC

36 ± 6

7 + 2

ND

ND

R-FB

43 ± 2

3 + 3

48 + 5

.3 ± 1

26 + 9

6 ± 8

ND

ND

46 + 1^

10 ± 3

55 ± 5

3 + 1

5 ± 0.5

Day 10
9 + 1

Day 21
5 + 2

Day 42
VC
R-FB

6 ± 1

All groups contained 6, animals (except Day 42, R-FB
group had 5 due to 1 death).
^ P < 0,05 compared to treatment control.

treated

* Values given as mean ± SD.
% Change B. Wt = Percent change in body weight = (ngcropsy
weight - day-0 weight)/day-0 weight•100.
R-FB = R-flurbiprofen.
S-Fb - S^flurbiprofen.
VC = Venicle Control (1% carboxymethylcellulose).
HCT = Hematocrit.
ND = None Detected.

Bioinvetsion = S-FB(jxg•ml"^)/[R-FB (|J,g'ml"^)+ S-FB (|j,g ml"^)]
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concentration) of R-FB.

Overall the levels of R-FB were

within previously reported values (Wechter et al. 1997).
Because mice are a bioinverting species, concentrations of

S-FB between 3 and 7 pg ml~^ correspond to approximately 5
to 9% bioinversion (Table 1).
Animal Deaths

One death occurred 35 days into treatment in an animal
scheduled to be treated with R-FB for 42 days (Table 1).
Prior to death, the animal demonstrated normal behavior,

weight gain, and no physical signs of morbidity.

This

animal was found dead in its cage probably due to
iatrogenic effects during the administration of oral
gavage,

Pharmacodynamics
Tumor E valuation

Tumor loads for individual animals decreased with time in

the R-FB treated animals.

The R-FB treated groups had

fewer total tumor numbers after 10 days of treatment and by
days 21 and 42 of treatment the tumors number was
significantly less by approximately 70% and 87% (p < 0.05),
respectively (Table 2).

In the control animals, the tumor
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Table 2. Tumor Counts Evaluated in C57BL/6J-APC'^'^'^/t
Mice Aged to 72 Days Old then Administered RFlurbiprofen Orally for Up to 42 Days.

„

,

,§

Treatment

_

Tumor #

^,

Tumor
^

Diameter

t ,

>

Tumor Area"^
,

(mm)

2%

(mm )

Day 0
0.5

± 0.17

± 0.13

0.6

± 0.24

+

0.07

0.3

± 0.11

0.7

± 0.10

0.6

± 0.17

0.5

±

0.2

±

0.8

± 0.10

0.2

±

± 0.13

24

+

VC

26

± 18

0.7

R-FB

27

±

8

0.5

VC

26

± 16

R-FB

16

±

7

25

±

7

0.8

± 0.08

7

±

2^

0.5

+

0.14^

1.0

+

0.21

1.2

± 0.49

0.4

±

0.25^

0.2

±

None

18

0.7

Day 4

Day 10

0.07^

0.08^

Day 21
VC
R-FB

0.15^

Day 42
27

VC
R-FB

4

± 10
±

2^

0.24^

^ All groups contained 6 animals (except Day 42,
R-FB treated group had 5 due to 1 death).

^ P < 0,05 compared to treatment control.
^ Values given as mean ± SD.
VC = Vehicle Control (1% CMC).

R-FB = R-flurbiprofen.

number remained stable at approximately 25 tumors per
animal for all treatment periods.
Treatment also influenced the size of the tumor.

Tumors from the Day-4 R-FB treated groups decreased in the

average tumor diameter by about 25% compared to the Day 0
control group (0.5 ± 0.07 mm vs. 0.7 ± 0.13 mm), and

maintained an average diameter of approximately 0.5 mm
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throughout the 42 days of treatment. , The tumor diameters
of the vehicTe-treated groups grew approximately 25% by day
42 of treatment (0,75 mm ± 0.13 at day 0 to 1.05 mm + 0.21

at day 42).

Since■the tumor diameters were, less in the

R-FB treated animals and greater in the vehicles-treated
groups,

a significant difference (p < 0.05) of approximately

25% was

established by Day-10 of treatment and had

increased to 38% and 55% by 21 and 42 days of treatment,
respectively.

Analysis of the data obtained from both

observers revealed no significant inter-Observer variance.
Gastrointestinal observations described as ulcers were

found in the early portion of this study (Table 3) .

These

ulcers were found predominantly in the R-FB. treatment
groups, with the majority occurring at Day-10 of treatment

and none being found at Day-42 of treatment.

No ulcers

were found in the vehicle-treated groups, with the
exception of one animal with one ulcer.

Fused villi were

found only in the treated groups, with the exception of one
animal in the Day-10 vehicle-treated group.

The Day-21

R-FB treated group contained the most fused villi, while
the Day-4 treated group had none.
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However, fused villi

Table 3.

Small Intestinal,Observations in

C57BL/6J-APC"^"/+ Mice Aged to 72 Days Old. then
R-Flurbiprofen Orally for Up to
42 Days.

Administered

Fused
Treatment

Ulcers''

Villi^

Day
N.O.

N.O.

VC

N.O.

N.O.

R- B

N.O.

2 ± 2

Nor

Day 4

Day 10
0.3 ± 0.8

VC
R-]B

Day

0.2 ± 0.4

3 ± 3 +

4 + 3+

N.O.

N.O.

7, ± 3 +

2 ± 2^

N.O.

N.O.

5 ± 4

N.O,

21

VC

R-FB

Day 4
VC

R-FB,

^ All g oups contained 6 animals (except Day,42, R-FB

treated group had 5 due to 1 death),

^ P < 0 05 compared to treatment control.

* Values given as mean ± SD.
N.O. = No

Observations,

VC = Ve hide
R-FB =

Control (1% CMC).

R-flurbiprofen.

were found from day 10 through day 42 in the R-FB treated
groups

Apoptotic Index

When R-FB was administered, the apoptotic index for the

crypts of Lieberkuhn sharply increased (Table 4).

A

significant two- to three-fold increase in the crypt
apoptotic index was observed in the R-FB treated groups
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Table 4. Apoptotic Index and Cell Positions of the Crypt,

Villus and Tumor Regions in C57BL/6J-APC^^^/+ Mice Aged to
72 Days Old then Administered R-Flurbiprofen Orally for Up
to 42 Days.
Treatment

Length
(days)

N

None

0

6

Treatment

Apoptotic Index^

# Cells/

(%)

Half-Region^

Crypt Region

0.71

VC

4

6

R-FB

4

4

VC

10

4

1.30

R-FB

10

1

3.73
o
OC
0.55
o
NC
1,98

±0.93

13.6

+0.8

±0.51

13.8

±1,0

±0.571

14.1

±0.5

+0.50

12.7

+0.2

15.0

±0,45

14.2

±0,4

±0.68^

13.0

±0.8

±0.79

13.5

±0.8

±0.32*'^

12.8

±0.6

0.39

±0.29

34.1

±1.7

6

0.23

±0.12

35.4

±1.9

4

0.30

±0.17

34.9

±2.1

±0.24

35.6

±3.8

VC

21

6

R-FB

21

6

VC

42

6

R-FB

42

5

O
CO
2.90

Non(e

0

6

VC

4
4

Villus Region

r-f:

VC

10

4 ^

0.2'2

R-FB

10

1

0.22

-

36.7

-

VC

21

6

0.27

±0.20

35.8

±2.3

R-FB

21

6

0.95

±0.51

31.0

±1.6'

VC

42

6

0.39

±0.28

34.8

±2.8

R-FB

42

5

0.85

±0.53

33.4

±2.5

None

0

5

0.11

±0.06
±0.02

Tumor Region

VC

4

6

0.08

R-FB

4

1

0.12

VC

10

3.

0.12

R-FB

10

0

±0.04

-

-

VC

21

6

0.08

±0.03

R-FB

21

3

0.29

±0.22

VC

42

6

0.08

±0.03

2

0.52

±0.58

R-FB

P < 0, 05

42

compared to day 0 control.

P ^ 0.05 compared to treatment control.

Values given as mean i SD.
VC = Vehicle Control . (1% CMC).
R-FB '= R-flurbiprofen.

N = Sample number

Apoptotic Index = # apoptotic cell/[# normal cells
# apoptotic cells] *100.
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compared to the vehicle-treated groups and was maintained

throughoiut the study.
incidencie

However the increase in the

of apoptotic cells did not result in a change

in the mumber

of cell positions lining the half-crypt

(Table 4).

The apoptotic index of the villus region did not match
that of the crypt region.

There was no difference in the

apoptoti.c index between the R-FB treated groups and the

vehicle-treated groups.

The number of cell positions

lining the half-villus also remained unchanged between the
vehicle and R-FB treated groups, with the exception of the
Day-21, groups.

The Day-21 R-FB treatment group showed an

apoptotic index decrease of approximately 13% compared to
the vehicle-treated group.

However, this difference was

not easily explained relative to the other R-FB treated
groups, since they did not demonstrate any change in the
apoptotic index.

The apoptotic index of tumor regions proved to be a
difficult measurement to obtain.

Because of the spacing of

tumors and the reduction of tumor number in R-FB treated
animals

the task of obtaining a slide section that bisects

a tumor

was very difficult and influenced the number of

animals

that were evaluated for tumor AI.
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Although there

.'

appeared to be a large increase in the apoptotic index of
Day-21 and Day-42 treated groups, the small and unequal
sample size severely affected statistical validation of
comparisons and prevented its analysis.
The multi-step process to prepare the samples for

TUNEL was vital to properly assess for apoptotic cells.
For an unidentified reason, the majority of the Day-10
animals could not be assessed because the paraffin embedded

tissue samples were either too fragile or brittle and,were
unable

:o withstand the TUNEL assay procedures
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CHAPTER FOUR
DISCUSSION AND CONCLUSION

Discussion
Pre vious

studies have shown that when R-flurbiprofen

was administered in the Min/+ mouse model it caused the

prevent!on and regression of Min/+ tumors.

This study

addresses the issue of the rate at which these tumors

regress and mode of action.

The data obtained from this

study demonstrate that R-flurbiprofen.administration in the
Min/+ mouse model caused: 1) a time-dependent decrease in
the total .number of developed tumors; 2) some involvement

of increasing apoptosis in tumor regions, 3) a significant
increase of the AI in normal appearing crypts of the small

intestine, and 4) no change in the AI of normal appearing
villus j-egions.

Previous studies involving other NSAIDs

have demonstrated.rapid regression of tumors and increased ,

AI in only the villus region (Boolbol et al. 1996, Chiu,
McEntee and Whelan 1997 and Mahmoud et al. . 1998). .Although

this study was contradictory regarding the AI incidence,
these results seem to be more rational based on GI

epithel. al cellular kinetics.
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Previous studies with R-FB in the Min/+ mouse model

found approximately 70% to 9Q% tumOr inhibition after 42 to
204 days of treatment (Wechter et al. 1997 and Wechter et
al. 2000).

In the current study, tumors decreased in

number gradually beginning between days 4 and 10 of drug
administration and continuing through day 42.

The tumor

regression observed was not as rapid as those exhibited in
a similc.r study using sulindac, a potent COX-2 inhibitor of
the acetic acid class of NSAID (Chiu, McEntee and Whelan

1997).

In the sulindac study, tumor loads were evaluated .

for up to 20 days, and displayed a rapid regression of
tumor number.

There was a rapid time-dependent decrease in

the tumor load of the sulindac treated animals.

However,

due to weak inhibition by R-FB of the COX enzymes, it was

anticipated that a slower regression would have occurred.
The assumption in this, study was that if R-FB affects
tumor growth by stimulating apoptosis, the apoptotic index
(Al) would increase in the tumor regions and slowly

decrease the tumor size until the tumor was no longer

present.

Obtaining an Al for the tumor regions in all

animals proved to be an difficult task.

The AI's that were

obtained were based on a small number of animals which were

not large enough to perform statistical,analyses.
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However,

as hypothesized the average tumor diameter did not decrease
over time but actually stayed relatively stable throughout

the study in the R-FB treated animals (Table 2).

This may

indicate that the loss of single tumors happens over a

relatively short time frame.

One method of rapid tumor

loss is when a whole tumor detaches from the wall of the
intestine and is lost into the lumen of the intestine

(desquamation),

This concept was considered in the

sulindac study mentioned above.

Because of the rapid

decrease in tumor counts and the inability to show an
increase in AI in the tumor regions, however those authors
also had difficulties with obtaining AI's (Chiu, McEntee

and Whelan 1997).

One piece of evidence that suggests

that desquamation may occur was one histological slide of_
the small intestine of an R-FB treated animal (Figure 2).

The arrow points to a large mass of tissue within the small
intestinal lumen with a large number (approximately 80%) of
the cells undergoing apoptosis or necrosis.

This

observation was seen over several serial sections and was^

believed not to be an artifact of preparation.

If these

tumors did in fact undergo desquamation, this rapid process
may leave behind an ulcer-like mucosa.
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Figure 2. Small intestinal lumen from a C57BL/6J-APC ^"/ +
/

mouse administered R-flurbiprofen orally.

The observations of ulcers in this study were first

thought to be the result of ulcer induction due to the
small amount of bidinversion from R-FB to S-FB present in
this model.

However, it seems that the ulcer appearance

may correlate better with tumor loss. The data show that

over time, ulcers appear first during times of more rapid
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tumor regression and they are absent at day 42, a time when

tumor regression rate may be at its lowest.

This

correlaljion may indicate that desquamatioh of the tumors
occurs, I leaving behind a region with ulcer-like appearance.
The observation of'fused villi was believed to be the

result if ulcers healing and this may still be the case..
Fused vlilli appeared after the presence of ulcers and were
then present throughout the rest of the study.

Although

the sullindac study (Chiu, McEntee and Whelan 1997) had

mentioied "crateriform lesions" (believed to be ulcers as
described by this paper), they had never suggested that

desquaiaation may be the cause. Although this study was not
designid to study the correlation between tumor regression,
ulcer jformation and fusion of villi these results warrant

furthJr analysis and should be the. subject of additional
studies.

ihe AI was studied in the crypt and villus regions of
normal appearing tissues.

Although the villus showed no

increase in AI over time, only the crypt region had a

significant increase in AI throughout the study.

This was

the Ojpposite of what was seen in the sulindac studies
(Boolbol et al. 1996, Chiu, McEntee and Whelan 1997 and

Mahmcpud et al. 1998), which reported the AI increases only
42

in the tjbp portion of the villus region. In the present
study tlrie AX of the crypt regions increased 2- to 5-fold

more thj.n the vehicle-treated groups. These results are
favorable, based on stem cell kinetics of the small

intestilie. These stem cells reside in the crypt of the
small intestine.

The number of stem cells has a positive

influenlce on the proliferation rate of the gastrointestinal
epithelium.

Studies suggest that the number of stem cells

and thi apoptosis rate are vital in maintaining constant
cell plpulations in of the gastrointestinal epithelium
(Potteli, Wilson and Booth 1997 and Renehan, Bach and Potten
2001).

This is because one stem cell can produce hundreds

of cells that migrate up the crypt and onto the villus.
When the number of stem cells goes unchecked by apoptosis,

tumorJgenesis can occur (Renehan, Bach and Potten 2001).,
Therefore, the ability of R-FB to increase the incidence of

apoptosis in the crypt opposed to the villus, gives greater

suppojrt to its anti-tumor activities and as a potential
therapeutic agent.

As with any drug, safety and tolerance are important
to the success of an efficacious chemotherapeutic agent.

The current study has shown that those animals treated with

R-FBI for 42 days had improved hematocrits from that of Day-

43

.

0 and Day-42 vehicle-treated animals.

Hematocrits have

proven tie be an important surrogate marker for tumor burden
in the Min/+ mice.

It is believed that as the tumor load

increases, hematocrit is adversely affected over time.

The,

one death that was observed in this study was believed to

be iatrLgenic in origin possibly during the administration
of oral! gavage.

Based on previous experience this is a

rare yet expected consequence of drug administration by the
use of oral gavage, especially in cases when no adverse
observations were noted prior to the animal's death.

Based

on theI current study, along with human studies, it is
further supported that R-FB is a safe and well tolerated

drug t|L administer as a chembtherapeutic agent (Quiggle et
al. 2o|oO).
Conclusion

|n conclusion, the data obtained from Min/+ mice
administered R-flurbiprOfen, demonstrated: 1) a steady
decrease in the total number of developed tumors over time;

2) soine involvement of increasing the AI in tumor regions,

3) a jsignificant increase of the AI in normal appearing
crypts of the small intestine, and 4) no change in the AI

of nirmal appearing villus regions. Increased incidence of
44

apoptosis in the crypts of normal appearing tissue supports
the tumor prevention activity of R-FB.

Although there was

some evidence of an increased incidence Of apoptosis in

tumor regions there was not an overall decrease in tumor
diameters.

Because of this, the possible roles of apoptosis

and des^uamation in tumor regression are still unknown.
With a better understanding of the rate at which tumors

,

decreas|e in number with R-FB administration, future studies
can be better designed to optimize the time frame in which

to capture the process of tumor regression.
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